transcutaneous electrical nerve stimulation (TENS, Stimpod NMS460)
Jump to navigation
Jump to search
Indications
- relief of chronic pain
- neurogenic pain
- functional abdominal pain in patients 11-18 years of age with irritable bowel syndrome (IB-Stim)[3]
* pain relief slower than intra-articular glucocorticoid
Contraindications
- not useful for lateral epicondylitis[1]
- should not be used near cardiac pacemaker (i.e. TENS for shoulder)
Procedure
- a small battery-operated device, worn by the patient, which provides continuous electrical pulses via surface electrodes applied to the skin with the goal of providing symptomatic relief by modifying pain perception (electroanalgesia)
- Stimpod NMS460 applies pulsed radiofrequency waveform to the affected area transcutaneously[2]
- IB-Stim[3]
- prescription-only device
- consist of a small single-use electrical nerve stimulator placed behind the patient's ear
- device contains a battery-powered chip that emits low-frequency electrical pulses to stimulate branches of cranial nerves continuously for 5 days
- device is replaced after 5 days
- stimulating nerve bundles in & around the ear is thought to provide pain relief
- patients can use the device for up to 3 consecutive weeks to reduce functional abdominal pain associated with IBS[3]
More general terms
More specific terms
- Cefaly transcutaneous electrical nerve stimulation (Cefaly)
- NSS-2 Bridge device
- trigeminal nerve stimulator; Monarch external trigeminal nerve stimulation (eTNS)
References
- ↑ 1.0 1.1 Chesterton LS et al Transcutaneous electrical nerve stimulation as adjunct to primary care management for tennis elbow: pragmatic randomised controlled trial (TATE trial). BMJ 2013;347:f5160 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/23999980 <Internet> http://www.bmj.com/content/347/bmj.f5160
- ↑ 2.0 2.1 Anderson P FDA Clears Noninvasive Device for Intractable Pain. Medscape. Aug 1, 2017 http://www.medscape.com/viewarticle/883653
- ↑ 3.0 3.1 3.2 3.3 FDA News Release. June 7, 2019 FDA permits marketing of first medical device for relief of pain associated with irritable bowel syndrome in patients 11-18 years of age. https://www.fda.gov/news-events/press-announcements/fda-permits-marketing-first-medical-device-relief-pain-associated-irritable-bowel-syndrome-patients